SPDR S&P Biotech ETF $XBI Shares Sold by Royal Fund Management LLC

Royal Fund Management LLC trimmed its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 18.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 125,943 shares of the exchange traded fund’s stock after selling 28,522 shares during the quarter. SPDR S&P Biotech ETF comprises about 1.5% of Royal Fund Management LLC’s holdings, making the stock its 7th largest position. Royal Fund Management LLC owned 0.19% of SPDR S&P Biotech ETF worth $19,859,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Ayalon Insurance Comp Ltd. boosted its position in shares of SPDR S&P Biotech ETF by 71.9% during the 3rd quarter. Ayalon Insurance Comp Ltd. now owns 95,600 shares of the exchange traded fund’s stock valued at $15,074,000 after acquiring an additional 40,000 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of SPDR S&P Biotech ETF during the second quarter worth about $19,270,000. Continuum Advisory LLC grew its holdings in shares of SPDR S&P Biotech ETF by 389.1% during the second quarter. Continuum Advisory LLC now owns 18,013 shares of the exchange traded fund’s stock worth $2,851,000 after purchasing an additional 14,330 shares in the last quarter. Syon Capital LLC increased its position in shares of SPDR S&P Biotech ETF by 67.9% in the second quarter. Syon Capital LLC now owns 23,562 shares of the exchange traded fund’s stock worth $3,729,000 after purchasing an additional 9,530 shares during the last quarter. Finally, TD Waterhouse Canada Inc. increased its position in shares of SPDR S&P Biotech ETF by 535.1% in the second quarter. TD Waterhouse Canada Inc. now owns 5,265 shares of the exchange traded fund’s stock worth $824,000 after purchasing an additional 4,436 shares during the last quarter.

SPDR S&P Biotech ETF Price Performance

Shares of XBI opened at $151.64 on Friday. The firm’s 50 day simple moving average is $157.56 and its 200 day simple moving average is $147.71. The company has a market capitalization of $10.31 billion, a P/E ratio of 11.47 and a beta of 0.83. SPDR S&P Biotech ETF has a 1-year low of $106.30 and a 1-year high of $169.89.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.